For the Inventor, By the Inventor

Enter assignee name

Aska Pharmaceutical Co., Ltd.

USPTO Granted Patents = 35

CIPO Patents = 8

EPO Patents = 23

Forward Citations = 59

Loading Chart...

Loading Chart...

69 inventors (with patents filed for the assignee):

Makoto Okada (9 out of 37 patents)

Youichi Nakano (7 out of 7 patents)

Hiroyuki Hayashi (6 out of 53 patents)

4. Shuichiro Sato (6 out of 11 patents)

5. Atsushi Shinbo (6 out of 6 patents)

6. Akira Asagarasu (6 out of 9 patents)

7. Hideo Kobayashi (6 out of 59 patents)

8. Koichi Miyazaki (5 out of 26 patents)

9. Hashime Kanazawa (5 out of 7 patents)

10. Kotaro Gotanda (5 out of 9 patents)

11. Takayoshi Nakagawa (5 out of 6 patents)

12. Shigeki Iwashita (4 out of 9 patents)

13. Takahisa Saito (4 out of 8 patents)

14. Takashi Nose (3 out of 149 patents)

15. Kenji Shimizu (3 out of 72 patents)

35 patents: Sort by Forward Citations

1. 12458650 - Urination disorder-improving agent (2025-11-04),

2. 11752102 - Powder preparation for nasal administration (2023-09-12),

3. 11234928 - Powder preparation for nasal administration (2022-02-01),

4. 10815268 - 15-oxosteroid compound and process for producing the same (2020-10-27),

5. 10710967 - Pyrimidine derivative (2020-07-14),

6. 10640749 - Mesenchymal stem cell and the method of use thereof (2020-05-05),

7. 10632065 - Microneedle device containing recombinant follicle stimulating hormone (2020-04-28),

8. 10508130 - Crystalline polymorph of 15B-hydroxy-osaterone acetate (2019-12-17),

9. 9643994 - Crystalline polymorphic form of ulipristal acetate (2017-05-09),

10. 9643993 - Crystalline polymorphic form of ulipristal acetate (2017-05-09),

11. 9365553 - Heterocyclic compound and H1 receptor antagonist (2016-06-14),

12. 9200008 - [object Object] (2015-12-01),

13. 9115344 - Mesenchymal stem cell and a method of use thereof (2015-08-25),

14. 9040536 - Substituted pyrrolo[1,2-a]quinoxalines as PDE9 inhibitors (2015-05-26),

15. 9006253 - Crystal of 2-(3,4-dichlorobenzyl)-5-methyl-4-oxo-3,4-dihydrothieno[2,3-D]pyrimidine-6-carboxylic acid (2015-04-14),

ASKA PHARMACEUTICAL CO., LTD. is a leading pharmaceutical company based in Japan. With years of experience in the industry, ASKA PHARMACEUTICAL is dedicated to researching, developing, and manufacturing high-quality pharmaceutical products. The company focuses on a range of therapeutic areas, including cardiovascular medicine, respiratory medicine, and central nervous system disorders. ASKA PHARMACEUTICAL is committed to improving the health and well-being of individuals worldwide through its innovative and effective pharmaceutical solutions.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 23 2025

35 Patents

#867 in Tokyo

#2,077 in Japan

#18,596 in the World

Aska Pharmaceutical Co., Ltd.

Forward Citations = 59

69 inventors:

Makoto Okada (9 out of 37 patents)

Youichi Nakano (7 out of 7 patents)

Hiroyuki Hayashi (6 out of 53 patents)

4. Shuichiro Sato (6 out of 11 patents)

5. Atsushi Shinbo (6 out of 6 patents)

Please report any incorrect information to support@idiyas.com

Loading…